Essential Continuous Glucose Monitoring Metrics: The Principal Dimensions of Glycemic Control in Diabetes
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Background: With the proliferation of continuous glucose monitoring (CGM), a number of metrics were developed to assess quality of glycemic control. Many of them are highly correlated. Thus, we aim to identify the principal dimensions of glycemic control—a minimal set of metrics, necessary and sufficient for comprehensive assessment of diabetes management. Methods: Seventy-five thousand five hundred sixty-three 2-week CGM profiles recorded in six studies by 790 individuals with type 1 or type 2 diabetes were used to compute mean glucose (MG), percentage time >180 mg/dL (TAR), >250 mg/dL (TAR2), <70 mg/dL (TBR), <54 mg/dL (TBR2), and coefficient of variation (CV). The true dimensionality of the glycemic-metric space was identified in a training set (53,380 profiles) and validated in an independent test set (22,183 profiles). Results: Correlation analysis identified two blocks of metrics—(MG, TAR, TAR2) and (TBR, TBR2, CV)—each with high internal correlation, but insignificant between-block correlation, suggesting that the true dimensionality of the glycemic-metric space is 2. Principal component analysis confirmed two essential metrics quantifying exposure to hyperglycemia (i.e., treatment efficacy) and risk for hypoglycemia (i.e., treatment safety), and explaining ∼90% of the variance in the training and test data. Conclusion: Two essential metrics, treatment efficacy and treatment safety, are necessary and sufficient to characterize glycemic control in diabetes. Thus, quantitatively, diabetes treatment optimization is reduced to a two-dimensional problem, meaning that minimizing both exposure to hyperglycemia and risk for hypoglycemia will lead to improvement in any other metric of glycemic control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 9×
“40 In the case of treatment directed by a health care provider, this optimization is based on review of an AGP and associated metrics 15 ; in the case of AID, it is driven by the control algorithm cost function.”
InfluentialSelf-citationSparse Principal Component Analysis
Zou, H., Hastie, T., & Tibshirani, R. (2006) · Journal of Computational and Graphical Statistics · doi:10.1198/106186006x113430 · Cited by 3,152
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 1×
“22 These metrics include multiple indicators of the time spent within specific glycemic ranges, measures of variability, and indices summarizing the adequacy of CGM data collection.”
Self-citationBeck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Self-citationLind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684 · cited 13×
“For example, GMI is a linear function of MG, 23 implying a correlation of 1.0, and TIR = 100 - TAR - TBR, by definition.”
InfluentialSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Beck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2855 · Cited by 635
A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
Breton, M. D., Kanapka, L. G., Beck, R. W., Ekhlaspour, L., Forlenza, G. P., Cengiz, E., Schoelwer, M., Ruedy, K. J., Jost, E., Carria, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004736 · Cited by 455 · cited 1×
“In 2019, the 14 metrics were further reduced to 10 standardized metrics for clinical care, 8 of which describe glycemic control—for example, MG, GMI 23 ), percentages in glycemic ranges, and CV. 15 We should immediately point out that many of these metrics are linearly dependent and most are highly…”
Aleppo, G., Ruedy, K. J., Riddlesworth, T. D., Kruger, D. F., Peters, A. L., Hirsch, I., Bergenstal, R. M., Toschi, E., Ahmann, A. J., Shah, V. N., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2482 · Cited by 329
Bergenstal, R. M., Ahmann, A. J., Bailey, T., Beck, R. W., Bissen, J., Buckingham, B., Deeb, L., Dolin, R. H., Garg, S. K., Goland, R., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0051 · Cited by 307
Klonoff, D. C., Wang, J., Rodbard, D., Kohn, M. A., Li, C., Liepmann, D., Kerr, D., Ahn, D., Peters, A. L., Umpierrez, G. E., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221085273 · Cited by 295
Self-citationMetrics for glycaemic control - from HbA1c to continuous glucose monitoring
Kovatchev, B. P. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.3 · Cited by 272 · cited 2×
“10 Glucose profiles were assessed through metrics such as mean glucose (MG), standard deviation, coefficient of variation (CV), M-value (quality scores for glucose control) that is based on a logarithmic transformation of the blood glucose (BG) deviation from a preset value, 11 the index of glycemic…”
Self-citationOne Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250
Self-citationAmbulatory Glucose Profile: Representation of Verified Self-Monitored Blood Glucose Data
Mazze, R. S., Lucido, D., Langer, O., Hartmann, K., & Rodbard, D. (1987) · Diabetes Care · doi:10.2337/diacare.10.1.111 · Cited by 144
Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring
Xing, D., Kollman, C., Beck, R. W., Tamborlane, W. V., Laffel, L., Buckingham, B. A., Wilson, D. M., Weinzimer, S., Fiallo-Scharer, R., & Ruedy for the Juvenile Diabetes Research Foundation Continuo, K. J. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0156 · Cited by 131
Beck, R. W., Riddlesworth, T. D., Ruedy, K. J., Kollman, C., Ahmann, A. J., Bergenstal, R. M., Bhargava, A., Bode, B. W., Haller, S., Kruger, D. F., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30217-6 · Cited by 119
Randomized Controlled Trial of Mobile Closed-Loop Control
Kovatchev, B., Anderson, S. M., Raghinaru, D., Kudva, Y. C., Laffel, L. M., Levy, C., Pinsker, J. E., Wadwa, R. P., Buckingham, B., Doyle, F. J., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1310 · Cited by 60
Self-citation
Cited by
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831
Self-citationJacobs, P. G., Herrero, P., Facchinetti, A., Vehi, J., Kovatchev, B., Breton, M. D., Cinar, A., Nikita, K. S., Doyle, F. J., Bondia, J., et al. (2024) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2023.3331297 · Cited by 113
Self-citationCastañeda, J., Arrieta, A., van den Heuvel, T., Battelino, T., & Cohen, O. (2024) · Diabetes Care · doi:10.2337/dc23-1581 · Cited by 107
Rebound Hypoglycemia and Hyperglycemia in Type 1 Diabetes
Hansen, K. W., & Bibby, B. M. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231168379 · Cited by 17
“24 Patients with more than four rebound hyperglycemic episodes per two weeks are characterized by an unfavorable combination of a slightly lower hypoglycemic nadir followed by a higher glycemic peak.”
Metadata
- Authors
- Montaser, E., Fabris, C., & Kovatchev, B.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2022-11-01
- Volume
- 24
- Issue
- 11
- Pages
- 797-804
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W4283077142
- Cited by
- 41
- References
- 19
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.